These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 22474603)

  • 1. Linking epigenetics to human disease and Rett syndrome: the emerging novel and challenging concepts in MeCP2 research.
    Zachariah RM; Rastegar M
    Neural Plast; 2012; 2012():415825. PubMed ID: 22474603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MeCP2 dysfunction in Rett syndrome and related disorders.
    Moretti P; Zoghbi HY
    Curr Opin Genet Dev; 2006 Jun; 16(3):276-81. PubMed ID: 16647848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving role of MeCP2 in Rett syndrome and autism.
    LaSalle JM; Yasui DH
    Epigenomics; 2009 Oct; 1(1):119-30. PubMed ID: 20473347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging physiological and pathological roles of MeCP2 in non-neurological systems.
    Wang J; Xiao Y; Liu C; Huang Y; Petersen RB; Zheng L; Huang K
    Arch Biochem Biophys; 2021 Mar; 700():108768. PubMed ID: 33485848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MeCP2 binds to non-CG methylated DNA as neurons mature, influencing transcription and the timing of onset for Rett syndrome.
    Chen L; Chen K; Lavery LA; Baker SA; Shaw CA; Li W; Zoghbi HY
    Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5509-14. PubMed ID: 25870282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Alpha-Synuclein Gene (SNCA) is a Genomic Target of Methyl-CpG Binding Protein 2 (MeCP2)-Implications for Parkinson's Disease and Rett Syndrome.
    Schmitt I; Evert BO; Sharma A; Khazneh H; Murgatroyd C; Wüllner U
    Mol Neurobiol; 2024 Oct; 61(10):7830-7844. PubMed ID: 38429622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of epigenetics in Rett syndrome.
    Kubota T; Miyake K; Hirasawa T
    Epigenomics; 2013; 5(5):583-92. PubMed ID: 24059803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuronal non-CG methylation is an essential target for MeCP2 function.
    Tillotson R; Cholewa-Waclaw J; Chhatbar K; Connelly JC; Kirschner SA; Webb S; Koerner MV; Selfridge J; Kelly DA; De Sousa D; Brown K; Lyst MJ; Kriaucionis S; Bird A
    Mol Cell; 2021 Mar; 81(6):1260-1275.e12. PubMed ID: 33561390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation mechanism and research progress of MeCP2 in Rett syndrome.
    Yang W; Pan H
    Yi Chuan; 2014 Jul; 36(7):625-30. PubMed ID: 25076025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MeCP2 in Rett syndrome: transcriptional repressor or chromatin architectural protein?
    Chadwick LH; Wade PA
    Curr Opin Genet Dev; 2007 Apr; 17(2):121-5. PubMed ID: 17317146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of MeCP2 in CNS development and function.
    Na ES; Monteggia LM
    Horm Behav; 2011 Mar; 59(3):364-8. PubMed ID: 20515694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radically truncated MeCP2 rescues Rett syndrome-like neurological defects.
    Tillotson R; Selfridge J; Koerner MV; Gadalla KKE; Guy J; De Sousa D; Hector RD; Cobb SR; Bird A
    Nature; 2017 Oct; 550(7676):398-401. PubMed ID: 29019980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MeCP2/YY1 interaction regulates ANT1 expression at 4q35: novel hints for Rett syndrome pathogenesis.
    Forlani G; Giarda E; Ala U; Di Cunto F; Salani M; Tupler R; Kilstrup-Nielsen C; Landsberger N
    Hum Mol Genet; 2010 Aug; 19(16):3114-23. PubMed ID: 20504995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of protein domains and Rett syndrome mutations indicate that multiple regions influence chromatin-binding dynamics of the chromatin-associated protein MECP2 in vivo.
    Kumar A; Kamboj S; Malone BM; Kudo S; Twiss JL; Czymmek KJ; LaSalle JM; Schanen NC
    J Cell Sci; 2008 Apr; 121(Pt 7):1128-37. PubMed ID: 18334558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The protocadherins, PCDHB1 and PCDH7, are regulated by MeCP2 in neuronal cells and brain tissues: implication for pathogenesis of Rett syndrome.
    Miyake K; Hirasawa T; Soutome M; Itoh M; Goto Y; Endoh K; Takahashi K; Kudo S; Nakagawa T; Yokoi S; Taira T; Inazawa J; Kubota T
    BMC Neurosci; 2011 Aug; 12():81. PubMed ID: 21824415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MECP2 mutations in Serbian Rett syndrome patients.
    Djarmati A; Dobricić V; Kecmanović M; Marsh P; Jancić-Stefanović J; Klein C; Djurić M; Romac S
    Acta Neurol Scand; 2007 Dec; 116(6):413-9. PubMed ID: 17986102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rett syndrome - biological pathways leading from MECP2 to disorder phenotypes.
    Ehrhart F; Coort SL; Cirillo E; Smeets E; Evelo CT; Curfs LM
    Orphanet J Rare Dis; 2016 Nov; 11(1):158. PubMed ID: 27884167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MeCP2, A Modulator of Neuronal Chromatin Organization Involved in Rett Syndrome.
    Martínez de Paz A; Ausió J
    Adv Exp Med Biol; 2017; 978():3-21. PubMed ID: 28523538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of DNA-methylation-dependent long gene repression in Rett syndrome.
    Gabel HW; Kinde B; Stroud H; Gilbert CS; Harmin DA; Kastan NR; Hemberg M; Ebert DH; Greenberg ME
    Nature; 2015 Jun; 522(7554):89-93. PubMed ID: 25762136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MECP2, a multi-talented modulator of chromatin architecture.
    Della Ragione F; Vacca M; Fioriniello S; Pepe G; D'Esposito M
    Brief Funct Genomics; 2016 Nov; 15(6):420-431. PubMed ID: 27296483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.